TriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated at Canaccord Genuity Group

Canaccord Genuity Group began coverage on shares of TriSalus Life Sciences (NASDAQ:TLSIFree Report) in a research report report published on Thursday morning, MarketBeat reports. The brokerage issued a buy rating and a $12.00 target price on the stock.

Other equities research analysts also recently issued reports about the company. Canaccord Genuity Group began coverage on TriSalus Life Sciences in a report on Thursday. They issued a buy rating and a $12.00 price target on the stock. Jonestrading assumed coverage on TriSalus Life Sciences in a research note on Friday, May 10th. They issued a buy rating and a $16.00 target price on the stock.

Check Out Our Latest Stock Report on TLSI

TriSalus Life Sciences Stock Down 3.8 %

NASDAQ TLSI opened at $7.16 on Thursday. TriSalus Life Sciences has a 52 week low of $3.32 and a 52 week high of $16.24. The company has a fifty day moving average of $9.46 and a two-hundred day moving average of $8.48.

TriSalus Life Sciences (NASDAQ:TLSIGet Free Report) last released its quarterly earnings results on Monday, April 1st. The company reported ($1.56) EPS for the quarter. The company had revenue of $5.72 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in TriSalus Life Sciences stock. Tyche Wealth Partners LLC bought a new position in TriSalus Life Sciences, Inc. (NASDAQ:TLSIFree Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 26,664 shares of the company’s stock, valued at approximately $225,000. Tyche Wealth Partners LLC owned 0.10% of TriSalus Life Sciences at the end of the most recent quarter. Institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

Further Reading

Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.